Michael Ehlers
About Michael Ehlers
Michael Ehlers serves as the Co-Founder and Board Chair at multiple biotechnology companies, including Aulos Bioscience and Replicate Bioscience, Inc. He has extensive experience in neuroscience and biotechnology, having held leadership roles at major institutions such as Pfizer and Duke University.
Work at Replicate Bioscience, Inc.
Michael Ehlers serves as Co-Founder and Board Chair at Replicate Bioscience, Inc. since 2021. The company focuses on developing innovative therapies utilizing synthetic RNA technologies. Ehlers' leadership plays a crucial role in guiding the strategic direction of the organization as it aims to address significant medical challenges.
Current Role at Apple Tree Partners
Ehlers has been the Chief Scientific Officer and Venture Partner at Apple Tree Partners since 2019. In this role, he contributes to the firm's investment strategies and scientific evaluations, leveraging his extensive background in neuroscience and biotechnology to identify promising opportunities in the life sciences sector.
Education and Expertise
Michael Ehlers completed his PhD in Medicine and Neuroscience at The Johns Hopkins University School of Medicine, where he also earned his MD. His educational background provides a strong foundation for his extensive career in neuroscience and biotechnology, enabling him to lead innovative research and development initiatives.
Previous Experience in Biotechnology
Ehlers has held several prominent positions in the biotechnology field. He served as Executive Vice President at Biogen from 2016 to 2019 and as Senior Vice President, Chief Scientific Officer for Neuroscience at Pfizer from 2010 to 2016. His experience includes founding and leading companies such as Ascidian Therapeutics and Intergalactic Therapeutics, focusing on developing therapies for various diseases.
Research and Development Focus
Ehlers leads research initiatives in biotechnology, particularly in synthetic RNA therapeutics and RNA exon editing. His work aims to create breakthrough therapies for a range of conditions, including ophthalmological, neurological, neuromuscular, and rare diseases. This focus reflects his commitment to advancing medical science and improving patient outcomes.